Advanced Solutions
for Advanced Pathology
Cytokeratin 5 (EP1601Y
†
)
Rabbit Monoclonal Antibody
Cat. No. Description
Volume
45281 IMPATH Cytokeratin 5 RTU R (EP1601Y)
50 Tests
44270 Cytokeratin 5 RTU R (EP1601Y)
7 ml Ready To Use
44561 Cytokeratin 5 0,1 R (EP1601Y)
100 µl liquid Concentrated
44562 Cytokeratin 5 1 R (EP1601Y)
1 ml liquid Concentrated
Product Specifications
Designation
IVD
Reactivity
Paraffin
Visualization
Cytoplasmic
Control
Mesothelioma, Prostate
Stability
Up to 36 mo. at 2-8°C
Isotype
IgG
Manual Protocol*
• Pretreatment: Heat Induced Epitope
Retrieval (HIER)
• Primary Antibody Incubation Time:
10-30min @ 25-37°C
• 2-step polymer detection
*Please refer to product insert for complete protocol.
ImPath Protocol*
• Dewax: Dewax Solution 2 (DS2)
• Pretreatment: Retrieval Solution pH 9.0
(TR1) 32min @ 98-103°C
• Primary Antibody Incubation Time:
10-90min @ 25-37°C
• HRP Polymer (Universal) or AP Polymer
(Universal) for 12 min
*Please refer to product insert for complete protocol.
Product Description
Cytokeratin 5 is an intermediate filament protein of 58 kD molecular weight within the cytokeratin family. It is a type II (basic) cytokeratin.
Antibodies to this protein identify basal cells of squamous and glandular epithelia, myoepithelia, and mesothelium.
Anti-cytokeratin 5 has been useful in the differential diagnosis of metastatic carcinoma in the pleura versus epithelioid mesothelioma. Epithelioid
mesotheliomas are strongly positive in all cases, but up to 11% of pulmonary adenocarinomas will show focal immunostaining. Almost all
squamous cell carcinomas, half of transitional carcinomas, and many undifferentiated large cell carcinomas immunostain with anti-CK 5. Anti-CK
5, along with anti-p63, affords a high sensitivity and specificity for squamous differentiation. Myoepithelial cells of the breast, glandular epithelia,
and basal cells of the prostate are labeled with anti-CK 5. This antibody, along with anti-CK 14, has found application in identifying basal-like
breast carcinoma, a tumor with poor prognosis. Some carcinomas of ovarian origin may display anti-CK 5 positivity.
Prostate: Malignant vs. Benign
CK 5
PSA/PSAP Androgen
Receptor
P504s
CK, 34βE12
p63
CK 14
Prostate Carcinoma
-
+
+
+
-
-
-
Benign Prostate
+
+
+
-/+
+
+
+
Breast Carcinoma
CK 5
CK 7
CK 20
ER/PR
CA15-3
CA19-9
p63
CD117
Infiltrating Ductal
Carcinoma
-/+
+
-
+
+
-
-
-
Adenoid Cystic Carcinoma
+
+
-
-
+
+
+
+
Squamous vs. Transitional Carcinoma
CK 5
CK, 34βE12
p63
Thrombo-
modulin
CK 7
CK 20
Uroplakin III
Squamous Carcinoma
+
+
+
+
-
-
-
Transitional Cell Carcinoma
-/+
+
+
+
+
+
+
Reference
1. Clarke CL, Sandle J, et al. J Pathol. 2004 Oct; 204(2):147-52.
2. Comin CE, Saieva C, Messerini L. Am J Surg Pathol. 2007 Aug; 31(8):1139-48.
3. Dabbs DJ, Chivukula M, Carter G, Bhargava R. Mod Pathol. 2006 Nov; 19(11):1506-11. Epub 2006 Aug 25.
4. Douglas-Jones A, Shah V, Morgan J, Dallimore N, Rashid M. Histopathology. 2005 Aug; 47(2):202-8.
5. Livasy CA, Perou CM, et al. Hum Pathol. 2007 Feb; 38(2):197-204.
97
